Dr. Craig Koniver

Thank you, Andrew.

Thank you, Andrew.

Thank you, Andrew.

Yeah.

Yeah.

Yeah.

For sure.

For sure.

For sure.

Yeah. I mean, just from a very elementary level, peptides are just chains of amino acids. So amino acids, all naturally occurring molecules. We call it a peptide if it's 40 amino acids or less. Call it a protein if it's 41 amino acids or more. The body makes, I think the last I read, 300,000 peptides. So it's a massive number.

Yeah. I mean, just from a very elementary level, peptides are just chains of amino acids. So amino acids, all naturally occurring molecules. We call it a peptide if it's 40 amino acids or less. Call it a protein if it's 41 amino acids or more. The body makes, I think the last I read, 300,000 peptides. So it's a massive number.

Yeah. I mean, just from a very elementary level, peptides are just chains of amino acids. So amino acids, all naturally occurring molecules. We call it a peptide if it's 40 amino acids or less. Call it a protein if it's 41 amino acids or more. The body makes, I think the last I read, 300,000 peptides. So it's a massive number.

We probably therapeutically are using closer to 150 over the years, which is obviously tiny compared to that. So to your point, this is blossoming. We've been using peptides for about eight years, a long time, but still very early in our understanding of how best to use peptides and how clinically we're going to get the most out of them. So it's exciting.

We probably therapeutically are using closer to 150 over the years, which is obviously tiny compared to that. So to your point, this is blossoming. We've been using peptides for about eight years, a long time, but still very early in our understanding of how best to use peptides and how clinically we're going to get the most out of them. So it's exciting.

We probably therapeutically are using closer to 150 over the years, which is obviously tiny compared to that. So to your point, this is blossoming. We've been using peptides for about eight years, a long time, but still very early in our understanding of how best to use peptides and how clinically we're going to get the most out of them. So it's exciting.

I think the weight loss aspect has only been a couple years. I mean, it's been tremendous how it's accelerated to, like, literally becoming the number one prescribed in America. You know, semiglutide ozempic was approved longer than that for type 2 diabetics, helping with, you know, glucose control and helping with glucose utilization.

I think the weight loss aspect has only been a couple years. I mean, it's been tremendous how it's accelerated to, like, literally becoming the number one prescribed in America. You know, semiglutide ozempic was approved longer than that for type 2 diabetics, helping with, you know, glucose control and helping with glucose utilization.

I think the weight loss aspect has only been a couple years. I mean, it's been tremendous how it's accelerated to, like, literally becoming the number one prescribed in America. You know, semiglutide ozempic was approved longer than that for type 2 diabetics, helping with, you know, glucose control and helping with glucose utilization.

And what they found as a side effect was that these people were losing weight. And then that word caught on. And what's interesting, and I don't think most people understand this, most of the medicines prescribed, particularly in America, are prescribed off-label, meaning they've never, ever been approved for what they're used. Isn't that right? Yeah, the vast majority. Yeah, are never approved.

And what they found as a side effect was that these people were losing weight. And then that word caught on. And what's interesting, and I don't think most people understand this, most of the medicines prescribed, particularly in America, are prescribed off-label, meaning they've never, ever been approved for what they're used. Isn't that right? Yeah, the vast majority. Yeah, are never approved.